Warburg Pincus related stories
All articles and analysis
- Sophiris Bio Appoints Knauf as Director
Sophiris Bio has appointed Noah Knauf as a director of the company. Knauf replaces Jonathan Leff, who has resigned as a director, as a Warburg Pincus nominee director. Knauf focuses on healthcare and life sciences as an investment professional at Warburg Pincus. Prior to joining Warburg Pincus, he was an associate at Parthenon Capital and a consultant with Bain & Company.
- Leff, 16-Year Warburg Veteran, Splits for Deerfield: CORRECTED
Jonathan Leff is leaving Warburg Pincus at the end of the year, two sources say. Leff, a Warburg MD, is joining Deerfield, the parent firm, as a partner and will be chairman of the Deerfield Institute effective Jan. 1, a person says.
- Rib-X Pharmaceuticals Secures Funds
Rib-X Pharmaceuticals has closed the first tranche of a $67.5 million Series 2 preferred stock financing. A second tranche is anticipated to close around the end of 2012. The round was led by new investor Vatera Healthcare Partners and included existing shareholders Warburg Pincus, ABS Ventures and Vox Equity Partners.
- Rib-X Pharmaceuticals Closes Tranche of $67.5M Financing.
Rib-X Pharmaceuticals Inc., a developer of treatments for acute bacterial skin and skin structure infections, has closed the first tranche of a $67.5 million Series 2 preferred stock financing. A second tranche is expected to close around the end of 2012, the company said in a press release. New investor Vatera Healthcare Partners led the latest infusion, which included existing shareholders Warburg Pincus, ABS Ventures and Vox Equity Partners.
- Proterra Raises $23M From Hennessey, Kleiner, GM, Others
Proterra Inc. said it raised $23 million of Series B financing in a round led by Hennessey Capital and joined by existing investors Kleiner Perkins Caufield & Byers, GM Ventures, Mitsui & Co. Global Investment, Inc., 88 Green Ventures and Vision Ridge Partners. Rajiv Ghatalia, founder of Hennessey Capital, will join the board of the electric bus maker as an advisor.
- Reuters - Final Bids Due for B&M
Advent is among a handful of private equity firms due to submit final round bids for discount retailer B&M, banking sources said on Tuesday, according to a Reuters report. Advent joins Blackstone, BC Partners, Clayton Dubilier & Rice and KKR to battle it out for a significant stake in the company, which has a price tag of 850 million pounds ($1.35 billion). The business has attracted interest from private equity firms as the discount retail sector is seen as a profitable business in the current difficult economic climate as people tighten their belts.